Skip to main content

Table 1 Patient characteristics

From: Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma

Characteristic

Reason for discontinuation

Overall

(n = 38)

Durable response (n = 27)

Toxicity

(n = 11)

Age

 Median (range)

58 (38 – 81)

52 (33—86)

58 (33—86)

Sex

 female

13 (48.1%)

3 (27.3%)

16 (42.1%)

 male

14 (51.9%)

8 (72.7%)

22 (57.9%)

AJCC

 IIIB

4 (14.8%)

1 (9.1%)

5 (13.2%)

 IV M1a

1 (3.7%)

3 (27.3%)

4 (10.5%)

 IV M1b

4 (14.8%)

2 (18.2%)

6 (15.8%)

 IV M1c

14 (51.9%)

5 (45.5%)

19 (50.0%)

 IV M1d

4 (14.8%)

0 (0%)

4 (10.5%)

BRAF status

 Mutated

10 (37.0%)

5 (45.5%)

15 (39.5%)

 Wildtype

17 (63.0%)

5 (45.5%)

22 (57.9%)

 Not reported

0 (0%)

1 (9.1%)

1 (2.6%)

Regimen

 Ipilimumab/Nivolumab

16 (59.3%)

8 (72.7%)

24 (63.2%)

 Nivolumab

4 (14.8%)

1 (9.1%)

5 (13.2%)

 Pembrolizumab

7 (25.9%)

2 (18.2%)

9 (23.7%)

Duration of immunotherapy

 Median (range)

24 (8.7 – 48)

1.3 (0.69—22)

19 (0.69—48)

Prior surgery

22 (81.5%)

9 (81.8%)

31 (81.6%)

Prior radiotherapy

8 (29.6%)

2 (18.2%)

10 (26.3%)

Prior systemic therapy

 IFN

8 (29.6%)

1 (9.1%)

9 (23.7%)

 Immunotherapy

7 (25.9%)

0 (0%)

7 (25.9%)

 Targeted therapy

4 (14.8%)

3 (27.3%)

7 (18.4%)

 Chemotherapy

2 (7.4%)

0 (0%)

2 (5.3%)

 Other

2 (7.4%)

1 (9.1%)

3 (7.9%)

Toxicity ≥ grade 3

12 (44.4%)

11 (100%)

23 (60.5%)

LDH elevateda

3 (11.1%)

2 (18.2%)

5 (13.2%)

S100 elevateda

0 (0%)

3 (27.3%)

3 (7.9%)

RECIST v1.1 groupa

 CR

11 (40.7%)

2 (18.2%)

13 (34.2%)

 PR

14 (51.9%)

7 (63.6%)

21 (55.3%)

 SD

2 (7.4%)

2 (18.2%)

4 (10.5%)

  1. aat time of discontinuation
  2. Abbreviations: AJCC American Joint Classification of Cancer